

.....

**Prescription of Narcotics for Heroin Addicts**

.....

# Medical Prescription of Narcotics

Vol. 1

Series Editors

*A. Uchtenhagen, Zürich*  
*F. Gutzwiller, Zürich*  
*A. Dobler-Mikola, Zürich*  
*T. Steffen, Zürich*  
*M. Rihs-Middel, Bern*

**KARGER**

Basel · Freiburg · Paris · London · New York ·  
New Delhi · Bangkok · Singapore · Tokyo · Sydney

.....

# Prescription of Narcotics for Heroin Addicts

**Main Results of the Swiss National Cohort Study**

*A. Uchtenhagen, Zürich*  
*A. Dobler-Mikola, Zürich*  
*T. Steffen, Zürich*  
*F. Gutzwiller, Zürich*  
*R. Blättler, Zürich*  
*S. Pfeifer, Zürich*

26 figures and 60 tables, 1999

**KARGER**

Basel · Freiburg · Paris · London · New York ·  
New Delhi · Bangkok · Singapore · Tokyo · Sydney

.....

**Ambros Uchtenhagen**  
**Anja Dobler-Mikola**  
**Thomas Steffen**  
**Richard Blättler**  
**Silvia Pfeifer**

Addiction Research Institute  
Konradstrasse 32  
CH-8005 Zürich

**Felix Gutzwiller**

Institute of Social and Preventive Medicine  
University of Zürich  
Sumatrastrasse 30  
CH-8006 Zürich

Library of Congress Cataloging-in-Publication Data

A. Uchtenhagen, A. Dobler-Mikola, T. Steffen, F. Gutzwiller, R. Blättler, S. Pfeifer.

Prescription of narcotics for heroin addicts : main result of the Swiss national cohort study / Ambros Uchtenhagen.

(Medical prescription of narcotics; vol. 1)

Includes bibliographical references and index.

1. Heroin habit – Treatment – Switzerland. 2. Narcotics – Therapeutic use. 3. Drug abuse – Treatment – Switzerland. 4. Narcotic addicts – Rehabilitation – Switzerland. I. Title. II. Series.

[DNLM: 1. Heroin Dependence – drug therapy. 2. Narcotics – therapeutic use. 3. Substance Abuse Treatment Centers – Switzerland. 4. Evaluation Studies. WM 288 U17n 1999]

RC568.H4U25 1999

616.86'32061 – dc21

DNLM/DLC for Library of Congress

ISSN 1423-5765

ISBN 3-8055-6791-X (hardcover: alk. paper)

**Drug Dosage.** The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1999 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)

www.karger.com

Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel

ISBN 3-8055-6791-X

.....

# Contents

<b>VII</b>	<b>Acknowledgements</b>	
<b>VIII</b>	<b>Abbreviations</b>	
<b>1</b>	<b>Executive Summary</b>	
<b>10</b>	<b>1 Programme Objectives</b>	
<b>13</b>	<b>2 Research Topics and Research Plan</b>	
<b>16</b>	<b>3 Research Organisation</b>	
<b>19</b>	<b>4 Presentation of Findings</b>	
<b>19</b>	4.1. Substance-Related Findings	
<b>19</b>	4.1.1. Dosages and Substance Combinations	
<b>23</b>	4.1.2. Pharmacology: Pharmacodynamics and Pharmacokinetics	
<b>28</b>	4.1.3. Toxicology: Side-Effects	
<b>33</b>	4.1.4. Summary of Randomised and Double-Blind Studies	
<b>34</b>	4.1.5. Therapeutic Suitability of Substances and Methods of Administration	
<b>36</b>	4.1.6. Open Questions	
<b>37</b>	4.2. Patient-Related Results	
<b>37</b>	4.2.1. Samples	
<b>39</b>	4.2.2. Characteristics of Patients	
<b>47</b>	4.2.3. Retention Rate	
<b>48</b>	4.2.4. Changes in Health Status	
<b>54</b>	4.2.5. Changes in Addictive and Risk Behaviour	
<b>58</b>	4.2.6. Changes in Social Integration	
<b>63</b>	4.2.7. Changes in Criminal Behaviour	
<b>69</b>	4.2.8. Terminations and Subsequent Treatments	

73	4.2.9. Deaths
74	4.2.10. Limitations of Findings
75	4.3. Service-Related Results
75	4.3.1. Implementation of Treatment Centres
80	4.3.2. Security Aspects
82	4.3.3. Integration of Narcotics Prescription Into Polyvalent Out-Patient Clinics
84	4.3.4. Integration of Narcotics Prescription Into a Penal Institution
88	4.3.5. Costs and Funding
91	4.3.6. A Cost-Benefit Analysis
94	4.3.7. Neighbourhood and Political Environment
96	4.3.8. Limitations of Findings
<b>97</b>	<b>5 Evaluation of the Results</b>
97	5.1. Research Design and Methodology
98	5.2. Outcome Criteria
99	5.3. Comparative Analysis of Findings from PROVE, from Residential Drug-Free Treatments and from Substitution Treatments Using Oral Methadone
109	5.4. Limitations of Study
<b>110</b>	<b>6 Conclusions and Recommendations</b>
110	6.1 Indication for Heroin-Assisted Treatment
111	6.2. Carrying Out Heroin-Assisted Treatment
112	6.3. Control Measures for Heroin-Assisted Treatment
112	6.4. Final Recommendation
113	<b>References</b>
115	<b>Subject Index</b>
119	<b>Postscript. Political Decisions and the Future of Heroin-Assisted Treatment in Switzerland</b>

.....

## Acknowledgements

We are grateful to all those programme participants who took the trouble to give interviews and provide information, and we hope that the findings from the research work will support them in their difficult journey.

Our thanks are also due to all those working in the treatment centres who, in addition to all their other duties, were receptive to and understanding of the research project and provided an enormous service in the collection of data.

We are grateful to local authority and police representatives from the cantons and cities concerned. Their support in setting up the extensive research programme was essential.

Acknowledgement and thanks are due to all the scientists and all the members of the evaluation team who contributed to the result and without whom our task could not have been carried out.

Special thanks go to the staff of the Swiss Federal Office of Public Health whose initiative and continued support made the project possible in the first place.

*Ambros Uchtenhagen  
Felix Gutzwiller  
Anja Dobler-Mikola  
Thomas Steffen  
Margaret Rihs-Middel*

The work of the following independent reviewers is gratefully acknowledged

Rudolf Brenneisen, Zürich  
Jean-Pierre Dauwalder, Lausanne  
Werner Fischer, Genève  
Peter Grob, Zürich  
Ueli Grüninger, Bern  
Claudia Honegger, Bern  
Claude Jeanrenaud, Neuchâtel

Martin Killias, Lausanne  
Philippe Lehmann, Bern  
Mathias Markert, Bern  
Jean Martin, Lausanne  
Mario Pajarola, Chur  
Marco Schärer, Solothurn

.....

## Abbreviations

FOPH	Swiss Federal Office of Public Health
CV	Cramers V, statistical unit of association
Drop-in	Treatment centre Luzern
FDPO	Federal Data Protection Officer
FOS	Research Association of Residential Treatment Centers
Gourrama	Treatment centre Solothurn
HealthEcon	Research Group on Health Economics Basel
Herol	Treatment centre Olten
Ikarus	Treatment centre Winterthur
IPSC	Institute of Police Science and of Criminology, Lausanne
Janus	Treatment centre Basel
KODA	Treatment centre Bern
KOST	Treatment centre in prison Oberschöngrün
Lifeline/Crossline	Treatment centre Zürich
MSH1	Treatment centre St. Gallen
PEPS	Treatment centre Genève
PROVE	Project on the Prescription of Narcotics
Project H	Treatment centre Thun
PROMI	Treatment centre Fribourg
SAMBAD	Documentation System for Out-Patients
SUPRAX	Treatment centre Biel
ZOKL	Treatment centre Zürich
ZOPA	Treatment centre Zug